Breaking into the animal health vaccines market requires overcoming high regulatory barriers and providing speed in response to outbreaks and evolving variants. Hanjo Hennemann shares how VEROVACCiNES leveraged a recombinant platform to rapidly design, test, and scale vaccines utilising regulatory pathways for broader and faster market entry.

Commercialising a new category of care requires more than product innovation. Rebecca Windsor, Director of Veterinary Affairs at Gallant, shares how education and developing trusted continuing education platforms have been central to preparing veterinarians for the clinical adoption of regenerative medicine.